BYSI

BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China

This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?

A small biopharma stock soars 198% after the company says it will seek FDA approval following a successful cancer-drug trial

BYSI Stock Price Increases Over 320% Pre-Market: Why It Happened

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney